We also postulate that ibrutinib’s irreversible ITK inhibitory effects may prove effective in a number of other autoimmune, inflammatory, and viral diseases, including influenza A and HIV/AIDS.
J&J has Letter from FDA calling ibrutinib a "Breakthrough", Celgene has nothing. End of Story.
If this company were a European or US growth Retailer it would be $15-20 a Share. China and lack of float are killing the price on this stock.
Also, Dr. Moller created the Sensei and Magellan and remains a large stock holder. The reason DaVinci can't do cardiovascular is Dr. Moller and Hansen hold the exclusive rights. The same as Dr. Moller and MAKO hold the exclusive rights for knee sugeries.
Thank you for the lesson, Dr. trainingforoldage. The owner and founder Dr. Moller invented the DaVinci but we know you know batter.
Go back into history and look at DaVinci. It took 7 years before DaVinci took off. They used to put up these low numbers for years. Magellan is the system that will lead to a big take off. Catheter is 1/2 the size allowing a larger segment of the population to have robotic surgery.
Shipped a total of 122 robotic systems worldwide since first commercial launch
Where does it say hospitals are returning them after they try them?????
Wake up people, hospitals are buying this once they use them for a while.
Full Year 2012 Summary and Recent Business Highlights
•Full Year 2012 Results: •Shipped 12 robotic catheter systems: 6 Magellan™ Robotic Systems (4 U.S. and 2 internationally) and 6 Sensei® X Robotic Catheter Systems (3 U.S. and 3 internationally) •3 of the shipped Magellan Robotic Systems and one of the shipped Sensei Robotic Systems were shipped under the company's commercial evaluation program
•Shipped a total of 122 robotic systems worldwide since first commercial launch
•Recognized revenue on 13 robotic systems (5 U.S. and 8 internationally) •8 of the systems recognized as revenue were shipped in 2012 and 5 were shipped in previous years
•We estimate a record 2,688 procedures performed, up 8% year over year
•Sold a record 2,807 catheters, up 1% year over year
Motley Fool has never bothered to put in real analysis on PCYC.
Take Dr. Buggy for example. He had a 150,000 options given years ago. He recently exercised and sold 50,000 shares for a cool 3million+.
Dr. Buggy is the lead scientist behind ibrutnib. Dr. Buggy came over from from Celera after Pharmacyclics purchased the company in 2006. Duggan rewarded Buggy with the option years ago. Buggy is just beginning to reap the reward for his work with this miracle drug.
Google It. Duggan Knows!!!